Charles River, Aitia collaborate on AI-powered drug discovery solution
Under the agreement, Aitia will deploy Charles River's Logica across its portfolio of novel drug targets to optimise…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
14 Nov 23
Under the agreement, Aitia will deploy Charles River's Logica across its portfolio of novel drug targets to optimise…
14 Nov 23
Royalty Pharma to provide R&D funding support of up to $125 million for the development of olanzapine LAI…
13 Nov 23
Novo Nordisk’s new investment will expand its Kalundborg facilities to support the current and future product portfolio within…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
13 Nov 23
Under the partnership, Roche will provide atezolizumab for use in combination with RZ-001, an enzyme-based cancer gene therapy,…
13 Nov 23
ProstACT GLOBAL is the first late-stage study to assess TLX591 in adult patients with PSMA-positive metastatic castrate-resistant prostate…
13 Nov 23
The approval was based on the results from two successful randomised, double-blind, active-controlled, multicentre Phase 3 trials which…
13 Nov 23
Both companies aim to expand their collaboration to cover the entire project, including the development, production, and clinical…
13 Nov 23
Trial expected to reach the primary endpoint of progression free survival in the second half of 2025
13 Nov 23
Investment of EUR 175 million reaffirms Sandoz commitment to long-term leadership in off-patent medicines
10 Nov 23
AstraZeneca will obtain exclusive rights to develop and commercialise Eccogene’s ECC5004 for all indications across the world, excluding…